Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARCUS W LEE

Allopathic & Osteopathic Physicians Family Medicine

NPI
1457364077
CMS profile
20974
Location
TULLAHOMA, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$413.66

22 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $413.66 22

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARCUS W LEE

NPI 1457364077 · CMS profile ID 20974

Allopathic & Osteopathic Physicians / Family Medicine

TULLAHOMA, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457364077?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARCUS W LEE, NPI 1457364077, CMS profile ID 20974. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457364077?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MARCUS W LEE, NPI 1457364077, CMS profile ID 20974. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457364077?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MARCUS W LEE, NPI 1457364077, CMS profile ID 20974, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1457364077?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

22 matching records · $413.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 22 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–22 of 22.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $20.7711/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206875198 CMS
ABBVIE INC. $16.1611/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202282775 CMS
ABBVIE INC. $17.4611/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202282773 CMS
Exact Sciences Corporation $15.6710/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235285536 CMS
Novo Nordisk Inc $24.3310/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188697900 CMS
Amgen Inc. $15.8910/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228632528 CMS
ABBVIE INC. $24.5209/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202282771 CMS
Novo Nordisk Inc $13.7609/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188518541 CMS
Lilly USA, LLC $20.0208/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186812713 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.2108/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225622328 CMS
AstraZeneca Pharmaceuticals LP $14.7408/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207235696 CMS
Amgen Inc. $14.5607/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227140076 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $29.0707/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241353638 CMS
Exact Sciences Corporation $16.3406/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235285534 CMS
Novo Nordisk Inc $19.4706/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188154923 CMS
Merck Sharp & Dohme LLC $17.4106/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238177451 CMS
Bayer Healthcare Pharmaceuticals Inc. $21.8806/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225622324 CMS
Eisai Inc. $14.1504/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244495864 CMS
Bayer Healthcare Pharmaceuticals Inc. $19.4503/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225622326 CMS
Novo Nordisk Inc $22.4603/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188321277 CMS
Exact Sciences Corporation $16.4102/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235285524 CMS
ABBVIE INC. $15.9301/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202282769 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,069.95 90
PY2021 $20.00 1
PY2024 $351.93 19
PY2025 $413.66 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $41,224.32 19
PY2021 Principal investigator $508,494.07 158
PY2020 Principal investigator $652,209.70 156
PY2019 Principal investigator $293,637.72 176

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

156 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $300.00 12/31/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721314717
Principal investigator 1 PFIZER INC. $921.60 12/30/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742892401
Principal investigator 1 PFIZER INC. $8,332.80 12/29/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742891873
Principal investigator 1 Novo Nordisk AS $41.00 12/23/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 822176593
Principal investigator 1 PFIZER INC. $12,337.92 12/23/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742892405
Principal investigator 1 Novo Nordisk AS $597.78 12/22/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366229
Principal investigator 1 Novo Nordisk AS $888.30 12/22/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366235
Principal investigator 1 Novo Nordisk AS $200.00 12/22/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366237
Principal investigator 1 Novo Nordisk AS $27.00 12/18/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 822171045
Principal investigator 1 PFIZER INC. $7,023.36 12/16/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742892407
Principal investigator 1 PFIZER INC. $5,644.80 12/12/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742891935
Principal investigator 1 Novo Nordisk AS $200.00 12/10/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366233
Principal investigator 1 PFIZER INC. $7,680.00 12/02/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742891933
Principal investigator 1 Novo Nordisk AS $358.02 11/30/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366227
Principal investigator 1 Novo Nordisk AS $3,288.60 11/30/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366231
Principal investigator 1 PFIZER INC. $17,721.60 11/28/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742916361
Principal investigator 1 Novo Nordisk AS $41.06 11/23/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366203
Principal investigator 1 Novo Nordisk AS $75.00 11/18/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366201
Principal investigator 1 PFIZER INC. $37,473.28 11/18/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742916307
Principal investigator 1 PFIZER INC. $17,688.32 11/17/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742916311
Principal investigator 1 Novo Nordisk AS $75.00 11/16/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366209
Principal investigator 1 Novo Nordisk AS $41.06 11/13/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366207
Principal investigator 1 PFIZER INC. $31,147.52 11/11/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742916363
Principal investigator 1 Novo Nordisk AS $41.06 11/06/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366205
Principal investigator 1 PFIZER INC. $43,184.64 10/31/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742916357
Principal investigator 1 Novo Nordisk AS $371.52 10/29/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366215
Principal investigator 1 Novo Nordisk AS $637.74 10/29/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366221
Principal investigator 1 PFIZER INC. $28,764.16 10/23/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742916313
Principal investigator 1 Allergan, Inc. $327.00 10/20/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721303965
Principal investigator 1 Novo Nordisk AS $41.06 10/15/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366073
Principal investigator 1 PFIZER INC. $40,979.20 10/14/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742916243
Principal investigator 1 PFIZER INC. $18,298.88 10/10/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742916239
Principal investigator 1 AbbVie Inc. $2,310.24 09/30/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
M16-100 No dispute reported 06/30/2026 721187933
Principal investigator 1 PFIZER INC. $46,438.40 09/30/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742948809
Principal investigator 1 Novo Nordisk AS $75.00 09/28/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366225
Principal investigator 1 PFIZER INC. $65,601.28 09/26/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742948611
Principal investigator 1 Novo Nordisk AS $594.54 09/24/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366219
Principal investigator 1 Novo Nordisk AS $41.06 09/24/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366223
Principal investigator 1 Novo Nordisk AS $827.28 09/22/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366213
Principal investigator 1 PFIZER INC. $50,039.04 09/16/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742948609
Principal investigator 1 PFIZER INC. $59,208.60 09/12/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742948615
Principal investigator 1 PFIZER INC. $49,386.24 09/10/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742948903
Principal investigator 1 AbbVie Inc. $110.70 08/28/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
M16-100 No dispute reported 06/30/2026 721182793
Principal investigator 1 Novo Nordisk AS $0.32 08/28/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366069
Principal investigator 1 Novo Nordisk AS $371.52 08/27/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366211
Principal investigator 1 Novo Nordisk AS $2,421.36 08/27/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366217
Principal investigator 1 PFIZER INC. $5,487.36 08/26/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742948899
Principal investigator 1 Novo Nordisk AS $23.46 08/21/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366071
Principal investigator 1 PFIZER INC. $7,000.00 08/18/2020 Non-covered Recipient Entity
Trinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742948905
Principal investigator 1 Allergan, Inc. $3,190.45 08/13/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721289863
Principal investigator 1 Novo Nordisk AS $23.46 08/12/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366065
Principal investigator 1 Novo Nordisk AS $23.46 08/06/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366067
Principal investigator 1 AbbVie Inc. $377.56 07/30/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
M16-100 No dispute reported 06/30/2026 721177477
Principal investigator 1 Novo Nordisk AS $637.74 07/30/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366063
Principal investigator 1 Novo Nordisk AS $1,114.56 07/28/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366061
Principal investigator 1 Allergan, Inc. $3,753.75 07/14/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721283763
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366075
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366077
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366079
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366081
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366083
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366085
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366087
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366089
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366091
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366093
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366095
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366097
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366099
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366101
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366103
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366105
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366107
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366109
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366111
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366113
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366115
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366117
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366119
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366121
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366123
Principal investigator 1 Novo Nordisk AS $5.10 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366125
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366127
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366129
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366131
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366133
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366135
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366137
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366139
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366141
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366143
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366145
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366147
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366149
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366151
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366153
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366155
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366157
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366159
Principal investigator 1 Novo Nordisk AS $6.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366161
Principal investigator 1 Novo Nordisk AS $360.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366163
Principal investigator 1 Novo Nordisk AS $360.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366165
Principal investigator 1 Novo Nordisk AS $360.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366167
Principal investigator 1 Novo Nordisk AS $360.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366169
Principal investigator 1 Novo Nordisk AS $360.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366171
Principal investigator 1 Novo Nordisk AS $360.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366173
Principal investigator 1 Novo Nordisk AS $360.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366175
Principal investigator 1 Novo Nordisk AS $360.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366177
Principal investigator 1 Novo Nordisk AS $360.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366179
Principal investigator 1 Novo Nordisk AS $360.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366181
Principal investigator 1 Novo Nordisk AS $360.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366183
Principal investigator 1 Novo Nordisk AS $360.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366185
Principal investigator 1 Novo Nordisk AS $2.65 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366187
Principal investigator 1 Novo Nordisk AS $0.56 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366189
Principal investigator 1 Novo Nordisk AS $4.90 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366191
Principal investigator 1 Novo Nordisk AS $30.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366193
Principal investigator 1 Novo Nordisk AS $3.25 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366195
Principal investigator 1 Novo Nordisk AS $4.50 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366197
Principal investigator 1 Novo Nordisk AS $18.00 07/07/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366199
Principal investigator 1 PFIZER INC. $4,941.92 07/02/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742942165
Principal investigator 1 PFIZER INC. $260.16 07/02/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742942779
Principal investigator 1 AbbVie Inc. $2,258.66 06/30/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
M16-100 No dispute reported 06/30/2026 721172819
Principal investigator 1 Novo Nordisk AS $371.52 06/25/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366059
Principal investigator 1 PFIZER INC. $4,487.98 06/04/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742942777
Principal investigator 1 Novo Nordisk AS $239.76 05/29/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366041
Principal investigator 1 Novo Nordisk AS $637.74 05/28/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366029
Principal investigator 1 Allergan, Inc. $2,971.60 05/14/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721275241
Principal investigator 1 AbbVie Inc. $1,745.60 04/30/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
M16-100 No dispute reported 06/30/2026 721163115
Principal investigator 1 Novo Nordisk AS $3,910.14 04/30/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366027
Principal investigator 1 Novo Nordisk AS $75.00 04/28/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366049
Principal investigator 1 Novo Nordisk AS $200.00 04/23/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366025
Principal investigator 1 Novo Nordisk AS $1,604.88 04/23/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366039
Principal investigator 1 Novo Nordisk AS $1,383.48 03/24/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366021
Principal investigator 1 Novo Nordisk AS $930.00 03/24/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366023
Principal investigator 1 Novo Nordisk AS $2,665.00 03/24/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366033
Principal investigator 1 Novo Nordisk AS $743.04 03/24/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366035
Principal investigator 1 Novo Nordisk AS $260.00 03/24/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366037
Principal investigator 1 Allergan, Inc. $8,752.35 03/16/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721264139
Principal investigator 1 Novo Nordisk AS $2,185.38 02/27/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366017
Principal investigator 1 Novo Nordisk AS $200.00 02/27/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366019
Principal investigator 1 Novo Nordisk AS $1,982.88 02/25/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366031
Principal investigator 1 Allergan, Inc. $2,809.15 02/14/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721257257
Principal investigator 1 Novo Nordisk AS $7.40 02/06/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366043
Principal investigator 1 Novo Nordisk AS $3.05 02/06/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366045
Principal investigator 1 Novo Nordisk AS $9.95 02/06/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366047
Principal investigator 1 PFIZER INC. $194.13 02/06/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742979793
Principal investigator 1 AbbVie Inc. $1,847.75 01/30/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
M16-100 No dispute reported 06/30/2026 721147733
Principal investigator 1 Novo Nordisk AS $2,781.00 01/28/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366013
Principal investigator 1 Novo Nordisk AS $2,572.56 01/28/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742366015
Principal investigator 1 Allergan, Inc. $250.00 01/16/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721248265
Principal investigator 1 Novo Nordisk AS $7.40 01/16/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366053
Principal investigator 1 Novo Nordisk AS $3.05 01/16/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366055
Principal investigator 1 Novo Nordisk AS $9.95 01/16/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366057
Principal investigator 1 Allergan, Inc. $86.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721246587
Principal investigator 1 Allergan, Inc. $10,371.15 01/14/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721247345
Principal investigator 1 Novo Nordisk AS $9.95 01/09/2020 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 742366051